Celgene Co. (NASDAQ:CELG) has been given an average rating of “Buy” by the thirty-five analysts that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $129.20.

Several research analysts have recently issued reports on CELG shares. Barclays increased their price objective on shares of Celgene from $135.00 to $140.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. Cantor Fitzgerald set a $162.00 price objective on shares of Celgene and gave the company a “buy” rating in a report on Monday, October 16th. Jefferies Group reiterated a “buy” rating and issued a $160.00 price objective on shares of Celgene in a report on Monday, October 16th. BMO Capital Markets increased their price objective on shares of Celgene from $160.00 to $167.00 and gave the company a “positive” rating in a report on Tuesday, October 17th. Finally, Sanford C. Bernstein started coverage on shares of Celgene in a report on Tuesday, October 17th. They issued an “outperform” rating and a $162.00 price objective for the company.

Large investors have recently modified their holdings of the stock. NF Trinity Capital Hong Kong Ltd boosted its stake in Celgene by 51.6% in the 4th quarter. NF Trinity Capital Hong Kong Ltd now owns 107,491 shares of the biopharmaceutical company’s stock worth $11,218,000 after purchasing an additional 36,574 shares during the period. Concentric Wealth Management LLC boosted its stake in Celgene by 6.9% in the 4th quarter. Concentric Wealth Management LLC now owns 12,176 shares of the biopharmaceutical company’s stock worth $1,271,000 after purchasing an additional 785 shares during the period. Saturna Capital CORP boosted its stake in Celgene by 1.0% in the 4th quarter. Saturna Capital CORP now owns 211,984 shares of the biopharmaceutical company’s stock worth $22,123,000 after purchasing an additional 2,125 shares during the period. Bank of The West boosted its stake in Celgene by 23.4% in the 4th quarter. Bank of The West now owns 8,571 shares of the biopharmaceutical company’s stock worth $895,000 after purchasing an additional 1,628 shares during the period. Finally, Majedie Asset Management Ltd boosted its stake in Celgene by 12.8% in the 4th quarter. Majedie Asset Management Ltd now owns 37,994 shares of the biopharmaceutical company’s stock worth $3,965,000 after purchasing an additional 4,313 shares during the period. Hedge funds and other institutional investors own 78.93% of the company’s stock.

Shares of Celgene (CELG) traded up $2.75 during trading hours on Tuesday, hitting $96.49. 7,874,276 shares of the company’s stock traded hands, compared to its average volume of 8,384,782. Celgene has a 12 month low of $92.85 and a 12 month high of $147.17. The firm has a market capitalization of $74,350.00, a price-to-earnings ratio of 26.73, a P/E/G ratio of 0.71 and a beta of 1.49. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.78 by $0.09. Celgene had a net margin of 22.38% and a return on equity of 64.14%. The company had revenue of $3.48 billion for the quarter, compared to analyst estimates of $3.46 billion. During the same quarter last year, the business earned $1.61 earnings per share. Celgene’s revenue was up 16.9% compared to the same quarter last year. sell-side analysts anticipate that Celgene will post 7.68 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Celgene Co. (CELG) Receives Consensus Recommendation of “Buy” from Brokerages” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/02/06/celgene-co-celg-receives-consensus-recommendation-of-buy-from-brokerages.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.